Patents Examined by H. Sarah Park
  • Patent number: 10966920
    Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: April 6, 2021
    Assignee: Amerilab Technologies, Inc.
    Inventors: Carrie Kraling, Sarah Olson, Shayna Jilek
  • Patent number: 10953130
    Abstract: A solid hemostatic composition for use within a biological tissue at an internal treatment site includes a biopolymer configured to cross-link with red blood cells at the site to facilitate clot formation at the site, a first thickener that includes (hydroxypropyl)methyl cellulose (HPMC), a second thickener that includes animal-derived gelatin, and a bioadhesive that includes a low molecular weight poly(lactide).
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: March 23, 2021
    Inventor: Victor Matthew Phillips
  • Patent number: 10925814
    Abstract: Stable cream gel dermatological/cosmetic compositions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one lipophilic compound and at least one gelling agent.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 23, 2021
    Inventors: Claire Mallard, Fabienne Louis, Emmanuelle At Guillet
  • Patent number: 10927209
    Abstract: An object of the present invention is to provide an aqueous dispersion for use in a cosmetic, which has both the flexibility and hair styling properties (hair set retention properties), and which allows for easily re-styling hair when the hair style once set has been disturbed; and a cosmetic including the same. In the above mentioned aqueous dispersion and the cosmetic, a polyurethane is used, which is obtainable from a polyol component including at least one type of a polyether polyol and a polyester polyol, and a polyvalent isocyanate component, wherein the polyol component includes: a polyether polyol containing as a major component a structural unit derived from a polyalkylene glycol having from 2 to 4 carbon atoms, and having a number average molecular weight of 400 or more and 4,000 or less; or a polyester polyol containing a structural unit derived from at least one type of dicarboxylic acid selected from the group consisting of phthalic acid, isophthalic acid and terephthalic acid.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: February 23, 2021
    Inventors: Shinya Miyata, Eri Hatakeyama, Ryosuke Kawasaki, Aiko Takeda
  • Patent number: 10918582
    Abstract: The invention relates to a liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and a niacinamide compound, and also to a cosmetic composition containing such a mixture. Use for caring for, making up and cleansing keratin materials.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: February 16, 2021
    Assignee: L'OREAL
    Inventors: Sofiane Ouattara, Veronique Chevalier
  • Patent number: 10888523
    Abstract: This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: January 12, 2021
    Inventor: Bhavishya Mittal
  • Patent number: 10864280
    Abstract: Disclosed herein are nanodroplet compositions composed of a copolymer with a hydrophilic block and a hydrophobic block, a poloxamer, an oil, an anti¬cancer agent, and optionally a lyoprotectant. The nanodroplet compositions exhibit low toxicity and are biodegradable, provide for slow, sustained release of the anti-cancer agent at tumor sites, and result in a greater reduction of tumor volume when administered to subjects with cancer as compared to several commercially-available products. Furthermore, the nanodroplet compositions can be imaged and their progress through the body tracked with magnetic resonance spectroscopy or ultrasound.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: December 15, 2020
    Inventor: Der-Yang Tien
  • Patent number: 10821204
    Abstract: The present invention provides polymers which can be used as tissue supplements or lubricants in vivo. The inventive polymers can be used as tissue-interpenetrating hydrogel supplements, viscosupplements, tribosupplements, viscoelastics, tissue space fillers, and/or anti-adhesive agents. Also provided are pharmaceutical compositions comprising the inventive polymers and methods of using them including, for example, in the treatment of arthritic and injured synovial joints; in reconstruction or cosmetic procedures, intervertebral disc repair, treatment of vocal cord problems, treatment of urinary incontinence, and prevention of adhesion formation following abdominal or gynecological surgery or malfunction of naturally lubricious mucosal tissue.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: November 3, 2020
    Inventors: Mark Grinstaff, Benjamin Goldman Cooper
  • Patent number: 10806700
    Abstract: Oral dosage forms for the delivery of therapeutic agents include mechanical fasteners for engaging tissue of the gastrointestinal tract.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: October 20, 2020
    Assignee: Covidien LP
    Inventors: Daniel Broom, Joshua Stopek
  • Patent number: 10799594
    Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 13, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Jeremiah A. Johnson, Longyan Liao
  • Patent number: 10765752
    Abstract: An iron-based composition is described. The composition can be used in conditions of total or relative iron deficiency. In particular, a solid composition is described, preferably in the form of powder or granules, for use in the treatment of disorders or diseases related to or derived from an iron deficiency. The composition is suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. Finally, a process for preparing the solid composition is also described.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: September 8, 2020
    Assignee: ALESCO S.R.L.
    Inventors: Andrea Lacorte, Germano Tarantino
  • Patent number: 10729641
    Abstract: The present invention relates to an inorganic material comprising particles of three-dimensional ordered macroporous structure comprising spherical pores, said pores having an average pore diameter ranging from 50 nm to 10 ?m, the pore diameter varying by no greater than 20%, the surface of said pores being coated by an absorber agent of the visible wavelength spectrum, said particles having an average largest dimension ranging from 1 to 50 ?m, and wherein said particles are coated with at least a hydrophobic component. The invention further relates to a process for preparing said inorganic material.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 4, 2020
    Inventors: Laurent Vidal, Andreas Stein, David Josephson
  • Patent number: 10722476
    Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: July 28, 2020
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
  • Patent number: 10701956
    Abstract: A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that predominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 7, 2020
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Christina Khoo, Kathy Gross
  • Patent number: 10696623
    Abstract: The present invention relates to a novel phenolic acid derivative compound with whitening and antioxidant activities and use thereof. The phenolic acid derivative compound is a compound represented by Formula 1, which is described in the specification, an isomer thereof or a salt thereof. The compound of the present invention has skin whitening activity to inhibit tyrosinase, thus being suitable for use in a pharmaceutical composition or cosmetic product for skin whitening. In addition, the compound of the present invention is suitable for the prevention or treatment of oxidation-derived skin abnormality or disease such as skin aging due to its antioxidant activity.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 30, 2020
    Assignee: DAEBONG LS, LTD
    Inventors: Jin Oh Park, Ji Won Lee, Jae Young Lee, Hye Ja Lee, Bo kyung Kwon
  • Patent number: 10682412
    Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: June 16, 2020
    Assignee: POLYPID LTD.
    Inventor: Noam Emanuel
  • Patent number: 10668031
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: June 2, 2020
    Assignee: Anji Pharma (US) LLC
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. Beeley
  • Patent number: 10668050
    Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: June 2, 2020
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg
  • Patent number: 10653131
    Abstract: A decontamination gel is provided consisting of a colloidal solution comprising 0.1% to 30% by mass, preferably 0.1% to 25% by mass, still more preferably from 5% to 25% by mass, even more preferably 8% to 20% by mass, based on the mass of the gel, of at least one inorganic viscosifying agent; 0.1 to 10 mol/L of gel, preferably 0.5 to 10 mol/L of gel, still more preferably 1 to 10 mol/L of gel of at least one active decontamination agent; 0.01% to 10% by mass, preferably 0.1% to 5% by mass based on the mass of the gel of at least one mineral pigment; optionally, 0.1% to 2% by mass based on the mass of the gel, of at least one surfactant; optionally, 0.05% to 5% by mass, preferably 0.05% to 2% by mass, based on the mass of the gel, of at least one super-absorbent polymer; and the balance of solvent.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: May 19, 2020
    Inventors: Amélie Ludwig, Frédéric Goettmann, Fabien Frances
  • Patent number: 10653698
    Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: May 19, 2020
    Assignees: Mezzion Pharma Co., Ltd., The Children's Hospital of Philadelphia
    Inventors: James L. Yeager, David J. Goldberg, Stephen M. Paridon